explore -WSS

explore

author：hotspot 2025-09-30 20:35:42 - browse：27767

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： In the gardens at Boston Children's Hospital, families find sanctuary

hotspot

WSS

FDA panel to weigh approval of NurOwn, controversial ALS drug

Device maker Teleflex to acquire urology company for $600M

Lasker Awards 2023: Winners in biomedical research

CommonSpirit Health keeps growing, even as it loses money

Experts study whether long Covid risk adds up with each reinfection

Drug for rare kidney disease narrowly misses mark in clinical trial

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

Biden warns of ‘dark winter’ during final presidental debate

Medicare details structure of new drug price negotiation program

How doctors’ personal politics affect patients

Medical records are filled with copy

Senate panel puts off hardest PBM reforms for another day

After affirmative action ruling, medical educators look to 'holistic review'

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Duchenne breakthrough therapy leaves behind pioneering families

How AI helped researchers track recovery from depression

entertainment

Truvian presents data for its desktop blood

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

How doctors’ personal politics affect patients

Changes to biosimilar regulatory framework must prioritize patients

The haunting brain science of long Covid

focus

Wikipedia

hotspot

explore